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Abstract
Thromboembolic events were described in patients with Chagas disease without cardiomy-
opathy. We aim to confirm if there is a hypercoagulable state in these patients and to deter-
mine if there is an early normalization of hemostasis factors after antiparasitic treatment.
Ninety-nine individuals from Chagas disease-endemic areas were classified in two groups:
G1, with T.cruzi infection (n = 56); G2, healthy individuals (n = 43). Twenty-four hemostasis
factors were measured at baseline. G1 patients treated with benznidazole were followed for
36 months, recording clinical parameters and performance of conventional serology, chemi-
luminescent enzyme-linked immunosorbent assay (trypomastigote-derived glycosylpho-
sphatidylinositol-anchored mucins), quantitative polymerase chain reaction, and
hemostasis tests every 6-month visits. Prothrombin fragment 1+2 (F1+2) and endogenous
thrombin potential (ETP) were abnormally expressed in 77% and 50% of infected patients
at baseline but returned to and remained at normal levels shortly after treatment in 76% and
96% of cases, respectively. Plasmin-antiplasmin complexes (PAP) were altered before
treatment in 32% of G1 patients but normalized in 94% of cases several months after treat-
ment. None of the patients with normal F1+2 values during follow-up had a positive qRT-
PCR result, but 3/24 patients (13%) with normal ETP values did. In a percentage of chronic
T. cruzi infected patients treated with benznidazole, altered coagulation markers returned
into normal levels. F1+2, ETP and PAP could be useful markers for assessing sustained
response to benznidazole.
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Author Summary
The manuscript describes the results of a study whose aim was to assess the tendency to
coagulate in people suffering from a parasitic infection frequent in Latin America named
T. cruzi infection or Chagas disease, by the study of several coagulation factors. According
to the state of the art in this topic, specific treatment for Chagas disease is recommended
in recent (acute) and late (chronic) stages of the infection. The effectiveness of current
available drugs in the chronic stage of infection is still a topic of debate due to inconsistent
results across studies and a lack of early measurable parameters of response to specific
treatment. Another aim of this study was to determine if the presence of an upregulated
procoagulative activity in plasma in people suffering T. cruzi infection could be used as
potential marker that indicates therapeutic response in people at chronic stage of the dis-
ease. The results of this study suggest that measurements of alterations of procoagulative
activity may be useful to indicate specific treatment for T. cruzi chronically infected
patients and new data concerning early response to treatment biomarkers.
Introduction
Chagas disease (CD) is one of 17 neglected tropical diseases recognized by the World Health
Organization. Caused by the protozoan parasite Trypanosoma cruzi, it mainly affects people
with poor socioeconomic status and limited health care access in endemic and nonendemic
countries. [1, 2]
Thrombosis is considered as a pathological deviation of haemostasis, and it is characterized
by intravascular thrombus formation and vessel occlusion. Perturbation of hemostasis is an
important factor in the pathogenesis of thromboembolic events, which can be caused by blood
flow dysregulation, endothelial injury, and coagulation system alterations.
Recently, is has been described that under certain circumstances thrombosis is a physiologi-
cal process that constitutes an intrinsic effector mechanism of innate immunity, and the pro-
cess has been defined as “immunothrombosis”. [3] It is activated after the recognition of
pathogens and damaged cells, and inhibits pathogen dissemination and survival. Immuno-
thrombosis can therefore be regarded as a newly identified, crucial element of intravascular
immunity, which is a part of the immune system that encompasses a wide range of host strate-
gies to detect and protect against pathogens in the vasculature. Dysregulation of immuno-
thrombosis is likely to constitute a key event in the development of thrombotic disorders. [3]
Infectious disease can cause a hypercoagulable state through the upregulation of tissue fac-
tor in monocytes, the generation of procoagulant microparticles, the activation of the coagula-
tion intrinsic pathway, platelet activation, and NETs (Neutrophil Extracellular Traps) release.
[3] Different infectious agents may cause different responses but a final degree of hypercoagu-
lability can be a common trait as one of the biological endpoints. Additionally, patients with
chronic inflammation may also present platelet adhesion events, which are considered inflam-
matory processes and can be observed in patients with chronic T. cruzi infection, even in the
asymptomatic stages. [4] Infection itself can cause vasculitis, increasing proinflammatory cyto-
kine levels and perpetuating the risk of thrombotic events. [5] In the case of the Chagas’ disease
the effect of hemostasis in the bradikinin formation, through the effect of factor XII activation
in the Kallikrein-Kinin system, can modify the type 1 immune response and then modulate the
antiparasite immunity as suggested in a mice model of subcutaneous infection by T.cruzi. [6]
Thromboembolic events and dilated cardiomyopathy, ventricular aneurysms, and intracavitary
thrombosis are associated with CD. [7, 8] Rheological factors can induce intraluminal thrombus
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formation with the risk of embolism. [9] Alterations of molecular markers of coagulation system
activation have been described in T. cruzi infection individuals with or without clinical thrombo-
sis. [9–12] Other factors, such as injury to vessel walls by parasites or changes in blood viscosity
due to host immune response, may influence in the development of thromboembolic events in T.
cruzi-infected individuals without Chagas cardiomyopathy or other vascular risk factors. [13]
Based on studies performed in humans with chronic T. cruzi infection, there are controversial
results regarding the existence of a prothrombotic status in T. cruzi-infected patients. [13,14]
There is an study in which a of higher prothrombotic status in the CD group was not found, but
the control group were individuals without T. cruzi infection and heart failure. [14] In previous
studies performed in murine models, several abnormalities of the heart microcirculation of indi-
viduals with chronic CD were pointed out, but they did not find evidence of thrombi and neither
thromboembolism. [15, 16] Higher levels of the hypercoagulability markers prothrombin frag-
ment 1+2 (F1+2), thrombin-antithrombin complexes (TAT), fibrinogen/fibrin degradation prod-
ucts, plasminogen activator inhibitor type 1 (PAI-1), and D-dimer have been reported in T. cruzi–
infected patients compared with healthy individuals. [10, 11] A pilot study performed by our
group showed that endogenous thrombin potential (ETP) and F1+2 levels were outside normal
ranges in 73% and 80% of T. cruzi–infected patients without advanced heart disease, respectively.
[12] We demonstrated a 100% and 73% decrease in these levels six months after treatment with
benznidazole. Thus, if they prove to remain stable in time, hypercoagulability factors could be
used as biomarkers of therapeutic response in CD. Besides, although whether or not chronic Cha-
gas disease is an independent vascular risk factor remains to be confirmed. [17,18]
While specific treatment is recommended in both acute and chronic stages of infection
[19,20], there are only two drugs (i.e., benznidazole and nifurtimox) available for the treatment
of CD. The mechanism of action of benznidazole relates to the nitro-reduction of components
of the parasite, the binding of metabolites of the nuclear DNA and k-DNA of T. cruzi and the
lipids and proteins of the parasite. [21] In adults, benznidazole has a high rate of adverse
effects, which can be classified into three groups: (i) hypersensitivity, including dermatitis with
cutaneous eruptions (usually appearing between days 7 and 10), myalgias, arthralgias, and
lymphadenopathy; (ii) polyneuropathy, paresthesias, and polineuritis usually during the 4th
week of treatment); and (iii) bone marrow disorders, such as thrombopenic purpura and
agranulocytosis (usually after the second week of treatment). [22]Furthermore, the effective-
ness of these drugs in the chronic stage of infection is still a topic of debate due to inconsistent
studies’ results [23–25] and a lack of early biomarkers of response to specific T. cruzi treatment
with benznidazole. [26]
Following on from our pilot study [12], here we increased the sample size and extended fol-
low-up to further investigate the value of hypercoagulability factors as biomarkers of treatment
response in CD. We also added current treatment response parameters measured by conven-
tional serology, serology for lytic anti-α-galactosyl (anti-α-Gal) antibodies against T.cruzi [27–
29], and quantitative reverse transcription polymerase chain reaction (qRT-PCR). [30]
The aims of the study were to investigate alterations of hypercoagulability factors in patients
chronically infected with T. cruzi and determine whether there is an early and sustainable
improvement of the hypercoagulability factors after antiparasitic treatment.
Methods
Ethics Statement
Written informed consent was obtained from participants before being recruited (all of them
were adults). Approval for the protocols and for the informed consent was obtained from the
Hospital Clínic of Barcelona Ethics Review Committee.
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Design and Setting
This is a descriptive study of 99 individuals (56 with T.cruzi infection and 43 healthy individu-
als) from Latin American, where CD is endemic. All the individuals were evaluated at the Cen-
tre for International Health at Hospital Clínic in Barcelona, Spain.
Recruitment and Participants
Ninety-nine individuals from CD-endemic areas living in Barcelona were invited to participate.
Inclusion criteria were an age of over 18 years and provision of signed informed consent.
Exclusion criteria were pregnancy, non-Chagasic cardiopathy, late chronic cardiac or digestive
forms of CD, other acute or chronic infections, inflammatory or immunological diseases, and
chronic systemic diseases (high blood pressure and diabetes).
Procedures
After signing the informed consent form, participants were asked for clinical and epidemiologi-
cal data, including area of origin and risk factors for the CD transmission. The information
recorded included vascular risk factors, toxic habits, and cardiological and/or vascular events.
Conventional serology of T.cruzi infection was established using two ELISA kits: a commer-
cial kit with recombinant antigens (BioELISA Chagas, Biokit S.A.,Barcelona-Spain) and an in-
house kit with whole T.cruzi epimastigote antigen, as described. [12, 31]. Diagnosis was con-
firmed by a positive result on both tests. [19] Following serological tests results, participants
were divided into two groups: those with T.cruzi infection (Group 1 [G1]) and those without
(Group 2 [G2]). All the participants underwent human immunodeficiency virus testing, basic
blood and biochemical tests (including renal and liver function), and specific evaluation of
hemostasis factors.
For the hemostasis studies, blood was collected in citrate-containing tubes (Becton Dickin-
son), samples were centrifuged, and platelet-poor plasma aliquots were frozen at –80°C until
assayed. Prothrombin time, activated partial thromboplastin time, coagulation factor VIII, pro-
tein C activity, free and total protein S levels, antithrombin and plasminogen activity, F1+2,
plasmin-antiplasmin complexes (PAP), factor VIIa, PAI-1, P-selectin, factor V Leiden and pro-
thrombin gene G20210A mutation, lupus anticoagulant and anticardiolipin antibodies were
measured as previously described. [12] D-dimer was measured using an automated turbidimet-
ric test (Siemens Healthcare Diagnostics) and ETP was assessed using a continuous chromo-
genic thrombin generation assay and ETP Curves software (Siemens). The ETP coagulation
test was initiated by using human recombinant tissue factor, phospholipids, and calcium ions.
ADAMTS-13 was measured using a commercial chromogenic method (American Diagnos-
tica). Factor XIIa was determined by a direct quantitative commercially available immunoassay
(Shield Diagnostics) with a highly specific monoclonal antibody that does not recognize its
zymogen factor XII.[32] Plasma tissue factor levels were determined using a commercial kit
(American Diagnostica) according to the manufacturer’s protocol. Plasma levels of vonWilleb-
rand factor antigen were determined by enzyme-linked immunosorbent assay (ELISA) (Cor-
genix). Procoagulant activity of microparticles was measured using a functional assay with the
addition of factors Xa, Va, and prothrombin after microparticle capture in the solid phase
using annexin V (Hyphen Biomed). Soluble CD40L was measured by ELISA (R&D Systems).
qRT-PCR [30] and a chemiluminescent ELISA assay based on a highly purified, trypomasti-
gote-derived glycosylphosphatidylinositol-anchored mucin (tGPI-mucin) antigen for the sero-
logical detection of lytic anti-α-Gal antibodies against T.cruzi (AT CL-ELISA) [27–29, 33–36],
were performed in G1 at month 0 (baseline), and 6, 12, 18, 24, 30, and 36 months post-treat-
ment. For AT CL-ELISA, a serum sample was considered positive when the titer was1.0 and
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negative when it was0.9. Inconclusive or equivocal results were determined by a titer
between 0.9 and 1.0. [27, 35]All sera were tested in duplicate and the results were expressed as
the mean of two simultaneous determinations.
G1 patients were studied using a protocol that included a 12-lead electrocardiogram, chest
X-ray, and echocardiogram. They were followed up every 6 months for at least 36 months. At
each visit, clinical data were collected and the following tests were performed: ELISA, AT
CL-ELISA, qRT-PCR, and hemostasis tests. Other tests were performed according to individual
symptoms. Specific treatment with benznidazole (5 mg/kg/day for 60 days) was offered to all T.
cruzi–infected patients, and those treated were monitored fortnightly for clinical and analytical
assessment. Treatment was considered complete when at least 80% of the total dose was
reached.
A hypercoagulable state is defined as the presence, in certain individuals, of thrombotic
potentialities that activate the endothelium and the formative elements of the blood (mainly,
platelets) that favors plasma kinetics that lead to the formation of thrombin, which disturbs
fibrinolytic activity and produces hemorheological changes with turbulence phenomena that
predispose to thrombogenesis. [18]
Statistical Analysis
Quantitative variables were presented as medians and interquartile range (IQR) and were com-
pared between groups using the Wilcoxon rank sum test. Qualitative variables were reported
using absolute frequencies and percentages and between-group comparisons were made using
Fisher’s exact test. Hypercoagulability biomarker variation over time was assessed using a
mixed-effect linear regression model with a random intercept structure. Hypercoagulability
factors were used as dependent variables and follow-up time as the explanatory variable, with
one category for each time point: baseline, month 6 (reference for comparisons), and months
12, 18, 24, and 36. This type of model allows for the inclusion of random effects in addition to
the overall error term. Random intercept regression was also used to assess whether antibody
levels measured by ELISA and AT CL-ELISA approached the negative threshold during fol-
low-up. The response variable was the distance from this threshold (i.e., the difference between
each ELISA or AT CL-ELISA value and the negative cutoff) and the explanatory variable was
the follow-up time from month six (reference) to month 36. The regression coefficients express
the effect estimate of follow-up on the outcome variable.
The pattern of the relationships between hypercoagulability biomarkers was assessed by
multiple correspondence analysis (MCA) using the Burt matrix approach. [37, 38] The MCA
represents a method for analyzing multi-way contingency table containing measure of corre-
spondence between row (subjects) and columns (levels of variables). The interpretation is
based upon proximities between levels of variables (or points) in a low-dimensional map. The
firsts dimensions (usually one or two) account for meaningful amounts of variance and are
those retained for the map definition and interpretation. The first dimension accounts for a
maximal amount of total variance in the observed variables. Under typical conditions, this
means that the first component will be correlated with at least some of the observed variables.
The second dimension has two important characteristics: it accounts for a maximal amount of
variance in the data set that is not accounted for by the first dimension, thus it is correlated
with some of the observed variables that not display strong correlations with dimension 1; and
it is uncorrelated with dimension 1. Looking at the map, the proximity between levels of differ-
ent variables means that these levels tend to appear together in the observations. Since the lev-
els of the same variable cannot occur together, the proximity between levels of the same
variable means that the groups of observations associated with these levels are themselves
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similar. A level far away from the origin (of the dimensions) means that is well-represented in
the map, thus that level is meaningful for the interpretation of the dimension(s). All levels that
are not useful for the solution are near the origin. Supplementary (passive) variables are those
not used for the solution but mapped in the graph in order to help in the interpretation.
The biomarkers were classified into three categories: normalization of values throughout
follow-up, non-sustained normalization during follow-up and normal values at baseline. Two
additional variables were considered: qRT-PCR results during follow-up (categories: always
negative and sometime positive) and level of adherence (categories: 80% and 100%). All the
tests were 2-tailed and the confidence level was set at 95%. The analyses were performed using
Stata 13 (Stata Corporation, College Station, TX, USA).
Results and Discussion
Ninety-nine individuals (76 women) were studied. Fifty-six of these (43 women) were T.cruzi–
positive (G1) and 43 (33 women) were T.cruzi–negative. The mean ages were 34 (SD, 9) years
for the overall group (range 17–56, median 33), 37 (SD, 9) years for G1, and 32 (SD, 7) years
for G2. Fifty G1 patients were treated with benznidazole (six were lost to follow-up before start-
ing treatment due to unexpected work-related changes in the migratory process). Forty-five
(90%) completed treatment. Eighty-six participants (87%) (51 [91%] in G1 and 35 [81%] in
G2) were from Bolivia. None of the participants traveled to their countries or other CD-
endemic areas during follow-up. The clinical and demographic data are summarized in
Table 1. The epidemiological and baseline clinical data were similar in both groups, making
them statistically comparable.
Comparison of the 24 hypercoagulability biomarkers at baseline between (untreated) G1
and G2 individuals showed statistically significant differences for D-dimer (P = .0262); F1+2
(abnormal values in 43/56 G1 patients [77%], P< .0001), PAP (abnormal values in 17/56 G1
patients [30%], P = .0111), P-selectin (abnormal values in 7/56 G1 patients [13%] P = .0177),
and ETP (abnormal values in 28/56 G1 patients [50%], P< .0013), and circulating
Table 1. Epidemiological data, vascular risk factors, and cardiovascular events in healthy and T. cruzi-infected individuals.
Group 2: Healthy Individuals n (%) Group 1: T. cruzi-Infected Patients (Baseline) n (%)
Country of origin Bolivia 35 (81) 51(91)
Argentina 1 (2) 2(4)
Brazil 1 (2) 1 (2)
Colombia 3 (7) 0
Ecuador 2 (5) 1 (2)
Paraguay 0 1 (2)
Peru 1 (2) 0
Toxic habits Smoking 1 (2) 1 (2)
Alcohol intake 5 (12) 1 (2)
Vascular risk factors High blood pressure 0 0
Hyperlipidemia 4 (9) 5 (9)
Diabetes mellitus 0 0
Cardiovascular events Atrial ﬁbrillation 0 0
Valvulopathy* 0 4 (8)
Cardiac failure 0 0
Myocardial ischemia 0 0
Stroke 0 0
doi:10.1371/journal.pntd.0004269.t001
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microparticles (P = .0112) (Table 2). D-dimer levels were normal in all the individuals in G1
and G2, and microparticles were within the normal range in a high percentage of patients (86%
in G1 and 93% in G2, P = .3402). Our findings showed that a high percentage of patients with
chronic T.cruzi infection have a hypercoagulable state regardless the clinical stage of disease,
thus confirming the observations of previous studies. [11–13]
Thirty-three (76%) of the 43 patients with abnormal baseline F1+2 values achieved normal
levels after a median follow-up of 9 month (IQR, 8). All but one of the 28 patients with abnor-
mal ETP values before treatment showed normal values at 6 months (IQR, 3). These values
were maintained throughout follow-up (30 months; IQR, 28) in 15 patients (60%). Fifteen of
the 17 patients with abnormal baseline PAP values showed normal values 7 months (IQR, 7)
after treatment and nine of these (60%) maintained these values throughout follow-up (28
months; IQR,11). However, PAP values at 12 and 48 months seemed to be higher than those at
6 months, but the confidence interval indicates a lack of precision for both time point effect
estimates (Table 3). Thus, once normalized, F1+2 and ETP levels did not increase again signifi-
cantly after treatment. Fig 1 shows a graphic representation of these results.
Table 2. Descriptive analysis and comparisons of hemostasis parameters between pretreatment Group 1 (N = 56) and Group 2 (N = 43).
VARIABLE Group 1 Median (IQR) [n] Group 2 Median (IQR) [n] P Value a Normal range (units)
D-dimer 228.5 (119.0) [56] 201.0 (125.0) [43] 0.0262 50–400 (μg/L)
Prothrombin fragment 1+2 1.8 (1.3) [56] 0.8 (0.4) [43] < 0.0001 0.40–1.1 (nM)
PAI-1 24.6 (14.5) [56] 21.3 (14.5) [43] 0.0680 4.0–43.0 (ng/mL)
Factor VIIa 3.5 (1.4) [56] 2.9 (1.8) [43] 0.4312 1.5–4.1 (ng/mL)
PAP complexes 360.9 (275.8) [56] 258.1 (225.8) [43] 0.0006 80–470 (μg/L)
P-selectin 41.8 (40.0) [56] 32.1 (21.7) [43] 0.0200 3–90 (μg/mL)
ETP 475.2 (99.2) [56] 412.4 (75.8) [43] <0.0001 351–473 (mEq)
Prothrombin time 98.5 (5.0) [56] 98.0 (5.0) [43] 0.4701 0.85–1.15 (ratio)/ 80–100 (%)
Attp 30.0 (3.0) [56] 30.0 (4.0) [43] 0.4849 25–35 (sec)
Fibrinogen 3.5 (0.8) [56] 3.4 (0.8) [43] 0.8540 1.5–4.5 (g/L)
Antithrombin 104.5 (16.5) [56] 101.0 (18.0) [43] 0.4518 60–140 (%)
Plasminogen 108.5 (17.5) [56] 107.0 (16.0) [43] 0.1467 60–140 (%)
Protein C 103.0 (30.5) [56] 104.0 (27.0) [43] 0.7082 60–140 (%)
Total protein S 87.0 (14.5) [56] 88.0 (12.0) [43] 0.8156 60–140 (%)
Free protein S 85.5 (11.5) [56] 88.0 (13.0) [43] 0.1125 60–140 (%)
FVIII 112.5 (51.0) [56] 103.0 (36.0) [43] 0.1391 60–140 (%)
FvWAg 136.0 (52.0) [56] 116.0 (46.0) [43] 0.0758 65–150 (U/dL)
Microparticles 21.1 (11.0) [56] 17.7 (13.5) [43] 0.0112 8–30 (nM)
CD40L 98.2 (39.3) [56] 89.0 (42.1) [43] 0.6952 30–145 (pg/mL)
Tissue factor 116.5 (50.1) [56] 124.2 (57.3) [43] 0.3737 80–280 (ng/mL)
ADAMT13 103.8 (41.9) [56] 97.9 (60.1) [43] 0.8905 50–120 (ng/mL)
Factor XIIa 3.7 (3.9) [56] 3.1 (4.6) [43] 0.3178 1.0–4.4 (ng/mL)
Factor V Leiden b No mutation 55 (98%) 42 (98%) 1.0000 c Mutations/no mutations
Heterocygote 1 (2%) 1 (2%)
G20210Ab No mutation 56 (100%) 43 (100%) Mutations/no mutations
a Wilcoxon rank sum test P value
b Absolute frequency (column percentage)
c Fisher’s exact test
doi:10.1371/journal.pntd.0004269.t002
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Table 3. Variations in hemostasis F1+2, ETP, and PAP during the follow-up of 50 treated patients.
F1+2b ETPb PAPb
Variable Effect Estimate (95% CI) P Value Effect Estimate (95% CI) P Value Effect Estimate (95% CI) P Value
TIME Baseline c 0.88 (0.66; 1.10) 52.58 (33.96; 71.21) 101.26 (48.39; 154.14)
6 mo 0 0 0
12 mo -0.08 (-0.36; 0.21) -8.54 (-31.96; 14.88) 65.30 (-1.58; 132.18)
18 mo -0.01 (-0.27; 0.25) < 0.0001 -6.06 (-27.87; 15.75) < 0.0001 29.03 (-33.24; 91.29) < 0.0001
24 mo 0.03 (-0.25; 0.30) 2.88 (-19.65; 25.41) -3.97 (-68.14; 60.20)
30 mo -0.10 (-0.39; 0.19) 13.19 (-10.58; 36.95) 49.83 (-17.91; 117.57)
36 mo 0.10 (-0.18; 0.37) 0.92 (-21.88; 23.73) -27.76 (-92.97; 37.45)
b F 1+2, prothrombin fragment 1+2; ETP, endogenous thrombin potential; PAP, plasmin-antiplasmin
c Baseline value compared to value at 6 months of follow-up.
doi:10.1371/journal.pntd.0004269.t003
Fig 1. Hemostasis factor levels (baseline and follow-up) in patients with altered levels before treatment who achieved levels within normal ranges
during follow-up. *The discontinuous red lines indicate patients who maintained normal values throughout follow-up. The continuous black lines indicate
patients who experienced a return to abnormal values at some time during the follow-up. Abbreviations: ETP, endogenous thrombin potential; F 1+2,
prothrombin fragment 1+2; PAP, plasmin-antiplasmin.
doi:10.1371/journal.pntd.0004269.g001
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F1+2 values are an indirect measure of the amount of thrombin generated in vivo (mainly
due to endothelial injury, even in subclinical states) [39], and ETP levels indicate the potential
amount of thrombin that can be formed when blood coagulation is activated through the addi-
tion of tissue factor. PAP complexes are markers of fibrinolysis. Upon activation, plasmin,
which is primarily responsible for a controlled and regulated dissolution of the fibrin polymers
into soluble fragments, is immediately inactivated by antiplasmin, forming PAP complexes.
[40] Therefore, it is conceivable that the increase formation of PAP complexes stems from
excessive formation of fibrin in the blood stream of untreated T. cruzi infected patients. Soluble
P-selectin is considered a biomarker of in vivo platelet activation. P-selectin is contained in the
α-granules of platelets; following platelet activation, the soluble form is expressed on the plate-
let surface and then shed by cleavage. P-selectin has been shown to act as a link between throm-
bosis and inflammation. [41] Additionally, the four biomarkers-F1+2, ETP, PAP complexes,
and P-selectin-reflect are highly stable over time.
A hypercoagulable state is a term that pretends to denominate a condition in which there is
an increased tendency toward blood clotting. There is not a universally accepted definition for
this state based in biomarkers values, but an increase in several of them suggests the possibility
of an increase in the person's chances of developing blood clots. The increases in F1+2, PAP
and ETP are congruent with this idea: F1+2 and PAP indicate the actual amount of thrombin
and plasmin formed, as markers in procoagulant and fibrinolysis pathways, respectively; and
ETP indicates the potential amount of thrombin that can be formed considering globally all
the activators, inhibitors and substrates of the hemostasis present in the plasma. The increase
observed in these biomarkers is good enough to be an argument to point out a hypercoagulable
state in patients with Chagas’ disease.
Sixteen (33%) of the 56 G1 patients had a positive qRT-PCR result at baseline, but only four
of these had a positive result after treatment (treatment failure rate of 25% in this subgroup).
Five of the 34 patients with a negative baseline qRT-PCR result showed a positive result during
follow-up. None of the patients with normal F1+2 values during follow-up had a positive
qRT-PCR result, but 3(13%) of the 24 patients with normal ETP values during follow-up did.
Of the patients with altered levels of F1+2, ETP, or PAP complexes at baseline, a positive
qRT-PCR result during follow-up was not significantly associated with changes observed in
lytic anti-α-Gal antibodies, F1+2, ETP, and/or PAP levels.
A positive qRT-PCR result after treatment in patients who achieved normalization of F1+2,
ETP, and/or PAP could mean that a decrease in parasite load is sufficient to modify the hyper-
coagulable state or that benznidazole, which acts on the redox system, could modify these bio-
markers without eliminating the parasites. This would limit the use of these factors as
biomarkers for parasite elimination, although they could be valuable indicators of treatment
response and add support to the theory that, by reverting the hypercoagulable state, benznida-
zole may also prevent clinical thrombotic events.
Conventional ELISA results were positive in all the patients in G1. Although, as expected,
antibodies remained positive throughout follow-up, a slight decrease was detected by the com-
mercial and in-house methods during this period. A statistically significant relevant decrease,
was only observed with the in-house test from month 18 onwards (P = .0006).
Lytic anti-α-Gal antibodies were positive in 52 (96%) of the 54 patients tested before treat-
ment, and in all patients AT CL-ELISA remained within positive levels to the end of the fol-
low-up (Fig 2). Besides, there was no correlation between lytic anti-α-Gal antibody assay and
the hemostasis factors evaluated. In relation to previous studies’ results, early decreases in lytic
anti-α-Gal antibodies were expected to be observed. On the contrary, a decrease in levels was
evident at month 12 and this was significant since month 18 and forward (P = .0052). [28, 34]
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Adherence to treatment was high, with only five patients not achieving 80% of the total
dose. All five patients showed abnormal F1+2 values throughout follow-up and 3 (60%) had
abnormal ETP and PAP values. One of the five patients had a positive qRT-PCR result during
follow-up, and all five maintained the same positive ELISA and AT CL-ELISA results through-
out follow-up. A large cohort of adolescents with T cruzi infection treated with benznidazole
showed seronegativity in lytic anti-α-Gal antibodies, as measured by AT CL-ELISA, in 58%
and 85% of the patients 36 and 72 months after treatment, respectively. [28, 34] The differences
between those studies and ours may be due to the nature of the cohorts (adolescents vs. adults)
and the stage of the disease. Nevertheless, both studies showed a similar trend towards a reduc-
tion in lytic anti-α-Gal antibodies following treatment with benznidazole.
We studied the relationship between normalization of hypercoagulability markers F1+2,
PAP, and ETP and qRT-PCR results by multiple correspondence analyses (MCA). Due to the
low rate of positive qRT-PCR results, this variable was used as a supplementary variable jointly
with treatment adherence. The MCA results (Fig 3) showed an association between complete
normalization of PAP and ETP levels and non-sustained and marginally abnormal values in F1
+2. These factors had the highest contribution and correlation in the positive part of the second
Fig 2. Variations in AT CL-ELISA levels.Months of follow-up predictive margins with 95% CI. Cutoff AT CL ELISA = 0.
doi:10.1371/journal.pntd.0004269.g002
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dimension, while normal baseline ETP and PAP values had the highest contribution and corre-
lation in the negative part. F1+2 normalization clearly characterized the positive part of the
first dimension, while non-sustained normalization of PAP and ETP values clearly character-
ized the negative part. In other words, the sustained normalization observed post-treatment in
PAP and ETP, could, despite the non-sustained normalization of F1+2 values, reflect response
to antiparasitic treatment due to the strong correlation between these three variables.
The projection of qRT-PCR results and adherence to treatment in the solution space pro-
vided little additional information. Consistently negative qRT-PCR results throughout follow-
up appear to be related to 100% treatment adherence.
In a recent study, the authors found that the serum samples of 37 individuals with chronic
Chagas disease showed an upregulation of specific fragments of apolipoprotein A-1 (Apo A1)
and one fibronectin fragment, that returned to normal levels in 43% of them three years after a
treatment with nifurtimox. [38] Apo A1 and fibronectin fragment were altered in all the 37
patients with T.cruzi infection before treatment, but the number of patients treated with that
normalized levels was lower than in our series (60% and 96% of patients who normalized F1+2
and ETP values).
This study has some limitations. Although the sample size was calculated to obtain sufficient
statistical power to answer the hypothesis, a larger sample may have detected differences that
would be expected to appear earlier (e.g., before 12 months). The lost to follow-up samples also
Fig 3. Multiple correspondence analysis coordinate plot. Biomarkers: N, sustained normalization of
values throughout follow-up; nsn: non-sustained normalization throughout follow-up; nbas, normal value at
baseline. Supplementary variables: qRT-PCR during follow-up: neg (negative); pos (positive); Level of
adherence: 80%; 100%. Abbreviations: ETP, endogenous thrombin potential; F1+2, prothrombin fragment
1+2; PCR, polymerase chain reaction.
doi:10.1371/journal.pntd.0004269.g003
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affected the estimates. Even within Spain, it is difficult to follow individuals with high migra-
tory mobility for long periods. In addition, the fact that only 30% of patients had a positive
baseline qRT-PCR result was a constraint for assessing the effect of treatment.
In conclusion, patients with chronic T.cruzi infection have a potential hypercoagulable
state, regardless of cardiological and/or digestive involvement. The hypercoagulability markers
F1+2 and ETP were abnormally expressed in a high percentage of patients with chronic T.cruzi
infection before treatment (77% and 50%, respectively) but returned to and remained at nor-
mal levels shortly after treatment in 76% and 96% of patients, respectively. Baseline PAP values
were altered in just 30% of patients before treatment, but normalized several months after
treatment in 88% of these. These three hypercoagulability biomarkers could be useful for
assessing short-term response to treatment. However, the fact that normal values were seen in
some infected patients, including some with positive post-treatment qRT-PCR results, reduces
their usefulness as universal biomarkers. The decrease in hypercoagulability factor levels could
be explained by a decrease in parasitemia or by other benznidazole effect.
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